KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Return on Equity (2016 - 2025)

Pacific Biosciences Of California (PACB) has 15 years of Return on Equity data on record, last reported at 26.37% in Q4 2025.

  • For Q4 2025, Return on Equity fell 2572.0% year-over-year to 26.37%; the TTM value through Dec 2025 reached 26.37%, down 2572.0%, while the annual FY2025 figure was 2.13%, 162.0% down from the prior year.
  • Return on Equity reached 26.37% in Q4 2025 per PACB's latest filing, down from 10.32% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.15% in Q3 2021 and bottomed at 26.37% in Q4 2025.
  • Average Return on Equity over 5 years is 2.64%, with a median of 0.47% recorded in 2023.
  • Peak YoY movement for Return on Equity: soared 158bps in 2021, then plummeted -2572bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.16% in 2021, then plummeted by -233bps to 0.53% in 2022, then rose by 21bps to 0.42% in 2023, then crashed by -54bps to 0.65% in 2024, then tumbled by -3984bps to 26.37% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 26.37% in Q4 2025, 10.32% in Q3 2025, and 6.87% in Q2 2025.